Fresenius Medical Care AG & Co. KGaA

Earnings Release • Jun 6, 2012

Goldman Sachs 33rd Annual Global Healthcare Conference

Rancho Palos Verdes, CA June 6, 2012

AGENDA

• 1 BUSINESS UPDATE
• 2 FINANCIALS & OUTLOOK
• 3 GROWTH STRATEGY
• 4 QUESTIONS & ANSWERS

BUSINESS UPDATE

© First Quarter 2012 3

Q1 | Overview

Strong operating performance

• Excellent revenue growth (North America +9%; International +12% cc)
• International EBIT-margin up +100 bps and North America up +30 bps (y-o-y)
• Investment gain as a result of the 49% equity interest in Renal Advantage, Inc.

\$ in m	Q1 2011	Q1 2012	Growth in %
Net revenue	2,984	3,249	9
Net income attributable to FMC AG & Co. KGaA	221	370	68
Earnings per share	0.73	1.22	67
Excluding investment gain:
Net income attributable to FMC AG & Co. KGaA	221	244	10
Earnings per share	0.73	0.80	10

Q1 | Revenue split by region

Total revenue improved 9% (10%cc) to \$ 3,249 m*

Q1 | Dialysis Services

Excellent revenue growth of 12% at constant currency

• Very good organic revenue growth of 5% in International
• Continued strong same market treatment growth of 4% globally
• North America with good growth after bundle implementation and supported by acquisitions

					Same market treatment
\$ in m	Q1 2011	Q1 2012	Growth in %	Growth in % cc	growth in %
North America	1,730	1,918	11	11	3
International	503	560	11	16	5
Total	2,233	2,478	11	12	4

cc = constant currency

Q1 | Dialysis Services | Quality outcomes

Excellent quality improvement programs	U. S.		EMEA		Asia-Pacific
% of patients	Q1 2011	Q1 2012	Q1 2011	Q1 2012	Q1 2011	Q1 2012
Kt/V ≥ 1.2	97	97	96	96	97	97
No catheter (all patients)	76	78	81	82	96	93
No catheter (>90 days)	80	82	85	85	97	94
Hemoglobin = 10 – 12 g/dl	73	78	54	57	57	59
Albumin ≥ 3.5 g/dl*	84	85	88	86	91	91
Phosphate ≤ 5.5 mg/dl	63	64	76	77	69	70
Calcium 8.4 – 10.2 mg/dl	79	82	78	77	74	75
Hospitalization days, per patient	9.8	9.8	9.8	9.4	4.9	4.4
* In the U.S. the albumin results are calculated with the BCG-method (bromcresol green)

Q1 | Dialysis Services | Clinic network status

Impressive global expansion

Clinics as of March 31, 2012	De novo Additions YTD 2012	Acquired YTD 2012
3,119	12	232
+ 13%
2,053	6	228
+ 13%
1,066	6	4
604	6	2
219		1
243		1
+ 13%

Q1 | Dialysis Products

Global total product growth of 6% cc (incl. internal)

Total product growth

• North America (2%)
• International +10% cc

\$ in m	Q1 2011	Q1 2012	Growth in %	Growth in % cc
Total product revenue	1,025	1,061	4	6
External revenue	751	771	3	5
North America	195	187	(4)	(4)
International	552	576	4	8
cc = constant currency

Q1 | Summary

• Continued global improvement in dialysis outcomes with focus on Anemia, Phosphorous and Hydration Management
• Large acquisitions are behind us and have achieved the desired global clinic network North America closed
• Progressing well with the integration of the acquisitions
• Continue to improve operating metrics while maintaining the highest quality of products and services
• Maintain tight cost control to compensate for global economic climate
• Confirm our 2012 guidance with confidence

2012 Expectations for North America - Update

Close Liberty / RAI in Q1 2012 and integrate through remainder of 2012

• Expect strong revenue growth
• Improve same store growth

Expect further improved patient care outcomes

Continued excellent operating performance

Close Liberty / RAI in Q1 2012

• Closed February 28, 2012.
• Expected to add annual revenues of around \$700 million and 201 clinics to FME's network for an investment, net of proceeds from the divestiture of approximately \$1.5 billion.
• Expected to be accretive to earnings in the first year after closing.
• Completed the sale of 44 dialysis clinics to Dialysis Newco, Inc. ("DSI Renal") as part of the FTC review. An additional 10 clinics are expected to be sold to DSI Renal following receipt of State regulatory approvals.

Expecting strong revenue growth in 2012
Maintaining or growing market position
	Growth (Q1 2012 /Q1 2011)
North America 	+ 9%
Services 	+11%
Products (Total Revenue (North America) 
HD& PD disposables 	+6.0%
Total Renal Products (excl. Pharma) 	+3.5%
Total RTG Products 	-1.6%
Products (External Revenue (North America adj.*) 
HD& PD disposables 	+6.3%
Total Renal Products (excl. Pharma) 	+1.6%
Total RTG Products 	-2.5%
*Adjusted to exclude Liberty/RAI from External Revenue

Continued excellent operating performance

Revenue and cost per treatment development in the U.S. leading to favourable EBIT-margin development in North America

FINANCIALS & OUTLOOK

© First Quarter 2012 15

Q1 | Profit & Loss

\$ in m	Q1 2011	Q1 2012	Growth in %
Net revenue	2,984	3,249	9	10% cc
Operating income (EBIT)	445	503	13
EBIT margin in %	14.9	15.5
Net interest expense	72	99
Income before taxes	373	531	42	Excluding investment gain \$404 m +8%
Income tax expense	124	137
Tax rate in %	33.3	25.8		Excluding investment gain 33.9%
Non-controlling interest	28	23
Net income attributable to FMC AG & Co. KGaA	221	370	68	Excluding investment gain \$244 m +10%
cc = constant currency

Q1 | Cash Flow

\$ in m	Q1 2011	Q1 2012	Growth in %
Operating cash flow	175	481	174	Favorable DSO development globally
% of revenue	6	15
Capital expenditures, net*	(113)	(122)
Free cash flow	62	359	477
Acquisitions and investments, net of divestitures*	(339)	(1,526)		Liberty acquisition closed Feb. 28, 2012
Free cash flow after acquisitions and investments	(277)	(1,167)	322

* A reconciliation to the most directly comparable U.S. GAAP financial measures is provided in the attachments

Q1 | Total Debt/EBITDA

Ratio decreased

• FY 2012 target of < 3.0
• Total debt of \$ 8,809 m and annualized EBITDA of \$ 2,975 m

2012 Outlook confirmed | excl. investment gain

Revenue growth in constant currency	• 13 -15%
Revenue	1) • ~ \$ 14.0 bn
EBIT-Margin	• ~ 16.9%
Net income, attributable to shareholders of FMC AG & Co. KGaA	• ~ \$ 1.14 bn
Acquisitions	• ~ \$ 1.8 bn
Capex	• ~ \$ 0.7 bn
Total debt / EBITDA	• < 3.0

1) US-GAAP revenue following first time adoption of Accounting Standards Codification 954-605 where patients service revenues is reduced for bad debt. The comparable revenue for the fiscal year 2011 is \$12,571 million

GROWTH STRATEGY

© First Quarter 2012 22

Market position by major product groups 2011

	Rank 1	Rank 2
Dialyzers	FME	Gambro
Dialysis machines	FME	Nikkiso
Hemodialysis concentrates	FME	Fuso
Bloodlines	FME	Gambro
Peritoneal dialysis products	Baxter	FME

World Leader in Dialysis Services¹

We lead in every major market, treating more than 237,574 patients worldwide

North America	FME		161,656
	DaVita		138,000
	Liberty Dialysis Inc.	17,150
Latin America	FME
	Baxter	8,800	25,759
	Diaverum	3,800
EMEA	FME
	KfH	18,500	48,452
	Diaverum	16,000
Asia Pacific	FME
	Showai-Kai	5,000	17,174
	Zenji-Kai	4,500
1 Based on company statements and estimates		# of patients

1970 1980 1990 2000 2010 2020 Development of Dialysis Patient Population Worldwide 2020: Estimates suggest an increase to 3.8 million dialysis patients No. of patients 2011 in % of total Growth rates 2011 North America 518,000 24% ~5% Europe 595,000 28% ~4% Latin America 225,000 10% ~5% Asia-Pacific 820,000 38% ~10% Worldwide 2,158,000 100% ~6% 8,000 80,000 200,000 500,000 900,000 1,500,000 2,500,000 3,500,000

Global Market Opportunity

Dialysis Market by Region Global Reimbursement for

© First Quarter 2012 28

Market Opportunities for Fresenius Medical Care

QUESTIONS & ANSWERS

© First Quarter 2012 33

CREATING A FUTURE WORTH LIVING. FOR PEOPLE. WORLDWIDE. EVERY DAY.

Thank you very much for your attention!

© First Quarter 2012 34

Attachment 1

Reconciliation of non-US-GAAP financial measures to most comparable US-GAAP measure

All numbers are in \$ m

Q1 2011	Q1 2012	Growth in %	Growth in % cc
			10
552	576	4	8
377	371	(2)	(2)
(181)	(184)
195	187	(4)	(4)
1,025	1,061	4	6
(274)	(290)
751	772	3	5
Q1 2011	Q1 2012
(117)	(124)
4	2
(113)	(122)
	644 (92)	682 (106)	6

Attachment 2

Reconciliation of non-US-GAAP financial measures to most comparable US-GAAP measure

All numbers are in \$ m

Cash Flow	Q1 2011	Q1 2012
Acquisitions, investments and net purchases of intangible assets	(339)	(1,703)
+ Proceeds from divestitures	-	177
= Acquisitions and investments, net of divestitures	(339)	(1,526)

Patients, treatments, clinics – Q1 2012	Clinics	Patients	Treatments in million
North America	2,053	161,656	5,75
Growth in %	13	17	10
International	1,066	91,385	3,47
Growth in %	13	16	18
Europe	604	48,452	1.84
Latin America	219	25,759	0.99
Asia-Pacific	243	17,174	0.63
TOTAL	3,119	253,041	9.21
Growth in %	13	17	13

Attachment 3

Reconciliation of non-US-GAAP financial measures to most comparable US-GAAP measure

All numbers are in \$ m

Debt	Q1 2012	FY2011	FY 2010	FY 2009	FY 2008	FY 2007
Short term borrowings (incl. A/R program1 )	104	99	671	316	684	217
+ Short term borrowing from related parties	15	28	10	10	1	2
+ Current portion of long-term debt and capital lease obligations	3,107	1,589	264	158	455	85
+ Current portion of trust preferred securities	-	-	625	-	-	670
+ Long-term debt and capital lease obligations less current portion	5,583	5,495	4,310	4,428	3,957	4,004
+ Trust preferred securities less current portion	-	-	-	656	641	664
TOTAL debt	8,809	7,211	5,880	5,568	5,738	5,642
EBITDA	Q1 2012	FY2011	FY 2010	FY 2009	FY 2008	FY 2007
Last twelve months operating income (EBIT)	2,284	2,075	1,924	1,756	1,672	1,580
+ Last twelve months depreciation and amortization	635	557	503	457	416	363
+ Non-cash charges	56	54	45	50	44	41
EBITDA (annualized)	2,975	2,686	2,472	2,263	2,132	1,984
Total Debt / EBITDA	2.96	2.69	2.38	2.46	2.69	2.84
1 2006 - 2010

Contacts

Fresenius Medical Care

Investor Relations Else-Kröner-Str. 1 61352 Bad Homburg v.d.H.

Ticker:	FME or FMS (NYSE)
WKN:	578 580
ISIN:	DE00057858002

• Oliver Maier Head of Investor Relations and Corporate Communications Tel: +49-(0) 6172 – 609 – 2601 Email: oliver.maier@fmc-ag.com
• Gerrit Jost Tel: +49-(0) 6172 – 609 – 5216 Email: gerrit.jost@fmc-ag.com
• Terry Morris Tel: +1- 800 – 948 – 2538 Email: terry.morris@fmc-na.com

Financial Calendar*

Aug 01, 2012 Report on 1st – 2nd quarter 2012

Oct 31, 2012 Report on 1st – 3rd quarter 2012

* Please notice that these dates might be subject to change

Constant Currency: Changes in revenue include the impact of changes in foreign currency exchange rates. We use the non-GAAP financial measure "at constant exchange rates" in our filings to show changes in our revenue without giving effect to period-to-period currency fluctuations. Under U.S. GAAP, revenues received in local (non-U.S. dollar) currency are translated into U.S. dollars at the average exchange rate for the period presented. When we use the term "constant currency," it means that we have translated local currency revenues for the current reporting period into U.S. dollars using the same average foreign currency exchange rates for the conversion of revenues into U.S. dollars that we used to translate local currency revenues for the comparable reporting period of the prior year. We then calculate the change, as a percentage, of the current period revenues using the prior period exchange rates versus the prior period revenues. This resulting percentage is a non-GAAP measure referring to a change as a percentage "at constant exchange rates."

We believe that revenue growth is a key indication of how a company is progressing from period to period and that the non-GAAP financial measure constant currency is useful to investors, lenders, and other creditors because such information enables them to gauge the impact of currency fluctuations on its revenue from period to period. However, we also believe that data on constant currency period-over-period changes have limitations, particularly as the currency effects that are eliminated could constitute a significant element of our revenue and could significantly impact our performance. We therefore limit our use of constant currency period-over-period changes to a measure for the impact of currency fluctuations on the translation of local currency revenue into U.S. dollars. We do not evaluate our results and performance without considering both constant currency period-over-period changes in non-U.S. GAAP revenue on the one hand and changes in revenue prepared in accordance with U.S. GAAP on the other. We caution the readers of this report to follow a similar approach by considering data on constant currency period-over-period changes only in addition to, and not as a substitute for or superior to, changes in revenue prepared in accordance with U.S. GAAP. We present the fluctuation derived from U.S. GAAP revenue next to the fluctuation derived from non-GAAP revenue. Because the reconciliation is inherent in the disclosure, we believe that a separate reconciliation would not provide any additional benefit.

Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

Goldman Sachs 33rd Annual Global Healthcare Conference

Rancho Palos Verdes, CA June 6, 2012